Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission

G Livingston, J Huntley, KY Liu, SG Costafreda… - The Lancet, 2024‏ - thelancet.com
Executive summary The 2024 update of the Lancet Commission on dementia provides new
hopeful evidence about dementia prevention, intervention, and care. As people live longer …

Blood biomarkers for Alzheimer's disease in clinical practice and trials

O Hansson, K Blennow, H Zetterberg, J Dage - Nature aging, 2023‏ - nature.com
Blood-based biomarkers hold great promise to revolutionize the diagnostic and prognostic
work-up of Alzheimer's disease (AD) in clinical practice. This is very timely, considering the …

Highly accurate blood test for Alzheimer's disease is similar or superior to clinical cerebrospinal fluid tests

NR Barthélemy, G Salvadó, SE Schindler, Y He… - Nature medicine, 2024‏ - nature.com
With the emergence of Alzheimer's disease (AD) disease-modifying therapies, identifying
patients who could benefit from these treatments becomes critical. In this study, we …

Organ aging signatures in the plasma proteome track health and disease

HSH Oh, J Rutledge, D Nachun, R Pálovics, O Abiose… - Nature, 2023‏ - nature.com
Animal studies show aging varies between individuals as well as between organs within an
individual,,–, but whether this is true in humans and its effect on age-related diseases is …

Diagnostic accuracy of a plasma phosphorylated tau 217 immunoassay for Alzheimer disease pathology

NJ Ashton, WS Brum, G Di Molfetta, AL Benedet… - JAMA …, 2024‏ - jamanetwork.com
Importance Phosphorylated tau (p-tau) is a specific blood biomarker for Alzheimer disease
(AD) pathology, with p-tau217 considered to have the most utility. However, availability of p …

Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup

CR Jack Jr, JS Andrews, TG Beach… - Alzheimer's & …, 2024‏ - Wiley Online Library
Abstract The National Institute on Aging and the Alzheimer's Association convened three
separate work groups in 2011 and single work groups in 2012 and 2018 to create …

Differential roles of Aβ42/40, p-tau231 and p-tau217 for Alzheimer's trial selection and disease monitoring

NJ Ashton, S Janelidze, N Mattsson-Carlgren… - Nature medicine, 2022‏ - nature.com
Blood biomarkers indicative of Alzheimer's disease (AD) pathology are altered in both
preclinical and symptomatic stages of the disease. Distinctive biomarkers may be optimal for …

Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline

R Ossenkoppele, A Pichet Binette, C Groot, R Smith… - Nature medicine, 2022‏ - nature.com
A major unanswered question in the dementia field is whether cognitively unimpaired
individuals who harbor both Alzheimer's disease neuropathological hallmarks (that is …

Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer's disease

M Milà-Alomà, NJ Ashton, M Shekari, G Salvadó… - Nature medicine, 2022‏ - nature.com
Blood biomarkers indicating elevated amyloid-β (Aβ) pathology in preclinical Alzheimer's
disease are needed to facilitate the initial screening process of participants in disease …

MEG3 activates necroptosis in human neuron xenografts modeling Alzheimer's disease

S Balusu, K Horré, N Thrupp, K Craessaerts, A Snellinx… - Science, 2023‏ - science.org
Neuronal cell loss is a defining feature of Alzheimer's disease (AD), but the underlying
mechanisms remain unclear. We xenografted human or mouse neurons into the brain of a …